BIT Capital’s Royalty Pharma RPRX Stock Holding History

BIT Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,018	Closed	-$469K	–	168
2023 Q1	$469K	Buy	+13,018	New	+$483K	0.07%	90

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BIT Capital's RPRX Position: Q2 2023 in Review

BIT Capital sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 13,018 shares — an estimated $469K sold.

BIT Capital first reported a position in RPRX in Q1 2023 and held it in 1 quarter. The position peaked at $469K in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

BIT Capital reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
BIT Capital sold 13,018 Royalty Pharma shares in Q2 2023, an estimated $469K.
BIT Capital first reported a position in Royalty Pharma in Q1 2023 and held it in 1 quarter.
BIT Capital's Royalty Pharma position peaked at $469K in Q1 2023.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on BIT Capital's 13F filing for Q2 2023, filed 12 Feb 2025.